NO20084055L - Nye primaere aminer - Google Patents

Nye primaere aminer

Info

Publication number
NO20084055L
NO20084055L NO20084055A NO20084055A NO20084055L NO 20084055 L NO20084055 L NO 20084055L NO 20084055 A NO20084055 A NO 20084055A NO 20084055 A NO20084055 A NO 20084055A NO 20084055 L NO20084055 L NO 20084055L
Authority
NO
Norway
Prior art keywords
primary amines
new primary
compounds
preparation
pharmaceutical compositions
Prior art date
Application number
NO20084055A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Weller
Sylvia Richard-Bildstein
Daniel Bur
Lubos Remen
Olivier Bezencon
Corinna Grisostomi
Olivier Corminboeuf
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20084055L publication Critical patent/NO20084055L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO20084055A 2006-03-03 2008-09-24 Nye primaere aminer NO20084055L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2006050678 2006-03-03
PCT/IB2007/050671 WO2007099509A2 (fr) 2006-03-03 2007-03-01 NouveLLES aminEs primaires

Publications (1)

Publication Number Publication Date
NO20084055L true NO20084055L (no) 2008-10-09

Family

ID=38459419

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084055A NO20084055L (no) 2006-03-03 2008-09-24 Nye primaere aminer

Country Status (16)

Country Link
US (1) US20090088457A1 (fr)
EP (1) EP2029542A2 (fr)
JP (1) JP2009528341A (fr)
KR (1) KR20080100382A (fr)
CN (1) CN101395135A (fr)
AR (1) AR059722A1 (fr)
AU (1) AU2007220149A1 (fr)
BR (1) BRPI0708487A2 (fr)
CA (1) CA2642424A1 (fr)
IL (1) IL193831A0 (fr)
MA (1) MA30292B1 (fr)
MX (1) MX2008011183A (fr)
NO (1) NO20084055L (fr)
TW (1) TW200800940A (fr)
WO (1) WO2007099509A2 (fr)
ZA (1) ZA200808419B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007000595A1 (es) * 2006-03-08 2008-01-04 Actelion Pharmaceuticals Ltd Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
CA2688057A1 (fr) 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Nouveaux inhibiteurs de rhenine
JP2010535716A (ja) * 2007-08-07 2010-11-25 メルク フロスト カナダ リミテツド レニン阻害剤
EP2190811B1 (fr) 2007-08-20 2013-08-07 Merck Canada Inc. Inhibiteurs de la rénine
JP2011500664A (ja) * 2007-10-15 2011-01-06 カディラ ヘルスケア リミティド レニン阻害剤
NZ589019A (en) 2008-05-05 2012-10-26 Merck Frosst Canada Ltd 3, 4 - substituted piperidine derivatives as renin inhibitors
WO2013088452A2 (fr) 2011-11-11 2013-06-20 Sun Pharma Advanced Research Company Ltd. Dérivés de quinoléine utilisés en tant qu'inhibiteurs de la rénine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009497A1 (en) * 2002-06-27 2006-01-12 Actelion Pharmaceuticals, Ltd. Novel tetrahydropyridine derivatives as renin inhibitors
CN1863773A (zh) * 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
JP2007513107A (ja) * 2003-12-05 2007-05-24 アクテリオン ファマシューティカルズ リミテッド ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体
AU2005276624B2 (en) * 2004-08-25 2011-09-29 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives as renin inhibitors

Also Published As

Publication number Publication date
AR059722A1 (es) 2008-04-23
AU2007220149A1 (en) 2007-09-07
BRPI0708487A2 (pt) 2011-05-31
IL193831A0 (en) 2009-08-03
US20090088457A1 (en) 2009-04-02
WO2007099509A3 (fr) 2007-12-21
MA30292B1 (fr) 2009-03-02
ZA200808419B (en) 2009-12-30
CN101395135A (zh) 2009-03-25
KR20080100382A (ko) 2008-11-17
TW200800940A (en) 2008-01-01
JP2009528341A (ja) 2009-08-06
EP2029542A2 (fr) 2009-03-04
WO2007099509A2 (fr) 2007-09-07
CA2642424A1 (fr) 2007-09-07
MX2008011183A (es) 2008-09-09

Similar Documents

Publication Publication Date Title
NO20084186L (no) Nye aminer
NO20083738L (no) Sekundaere aminer som renininhibitorer
NO20090628L (no) Pyridizinon derivativater
NO20085212L (no) Nye pyridinanaloger
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20071593L (no) Pyrimidinderivater
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20076448L (no) Novel piperidine carboxylic acid amide derivatives
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
EA200870217A1 (ru) 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
NO20082269L (no) Nye piperaziner som antimalariamidler
NO20050290L (no) Nye tetrahydropyridin-derivater som renin-inhibitorer
NO20063469L (no) Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
ATE500222T1 (de) Benzamid- und heteroarenderivate als cetp- inhibitoren
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
TW200801003A (en) Novel compounds
NO20072005L (no) Nye heterocykliske amider
NO20085214L (no) Nye pyridinanaloger
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
NO20091990L (no) Substituerte pyrazoler, sammensetninger inneholdende disse, fremgangsmate for fremstilling og anvendelse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application